10
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Green Renal Replacement Therapy: Caring for the Environment

      Submit here before July 31, 2024

      About Blood Purification: 3.0 Impact Factor I 5.6 CiteScore I 0.83 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Pyruvate Tolerance Test in Chronic Uremic Patients

      research-article
      , , ,
      Nephron
      S. Karger AG
      Pyruvate metabolism, Uremia, Glucose intolerance, 2-oxoglutarate

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          After intravenous pyruvate administration, the rate of decay of the blood pyruvate was significantly lower in the chronic uremic patients than in the healthy subjects. This difference could not be ascribed to a reduced renal excretion of pyruvate. Lower blood 2-oxoglutarate levels were found during the test in chronic uremic patients. The impaired glucose tolerance observed in chronic uremia could in part depend on a reduced pyruvate oxidation in the citric acid cycle.

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          1660-8151
          2235-3186
          1973
          1973
          27 November 2008
          : 10
          : 4
          : 232-237
          Affiliations
          Institute of Medical Pathology, Section of Nephrology, University of Padova, Padova
          Article
          180192 Nephron 1973;10:232–237
          10.1159/000180192
          4701578
          77bc8556-3aa3-4e97-838d-866a27424f28
          © 1973 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          Page count
          Pages: 6
          Categories
          Paper

          Cardiovascular Medicine,Nephrology
          Pyruvate metabolism,Uremia,Glucose intolerance,2-oxoglutarate
          Cardiovascular Medicine, Nephrology
          Pyruvate metabolism, Uremia, Glucose intolerance, 2-oxoglutarate

          Comments

          Comment on this article